4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis

4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis

The KRAS mutation is one of the leading driver mutations in colorectal cancer (CRC), and it is usually associated with poor prognosis and drug resistance. Therapies targeting the epidermal growth factor receptor (EFGR) are widely used for end-stage CRC. However, patients with KRAS mutant genes canno...

Full description

Bibliographic Details
Main Authors: Yi Cheng Chu, Tung-Yao Tsai, Vijesh Kumar Yadav, Li Deng, Chun-Chih Huang, Yew-Min Tzeng, Chi-Tai Yeh, Ming-Yao Chen
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:International Journal of Molecular Sciences
Subjects:
4-AAQB
cetuximab
KRAS mutation
resistance
colorectal cancer
Online Access:https://www.mdpi.com/1422-0067/22/14/7508

Similar Items

Similar Items